Scinai Immunotherapeutics Ltd.

Equities

SCNI

US09073Q2049

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
0.519 USD +3.80% Intraday chart for Scinai Immunotherapeutics Ltd. -0.19% -12.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Scinai Immunotherapeutics Ltd. Appoints Liat Halpert as Head of Business Development and Sales CI
Scinai Immunotherapeutics Ltd. announced that it has received $1.694259 million in funding CI
Transcript : Scinai Immunotherapeutics Ltd. - Special Call
Scinai Immunotherapeutics Exercises Outstanding Warrants for $1.69 Million in Proceeds MT
Scinai Immunotherapeutics Ltd. announced that it expects to receive $1.694259 million in funding CI
Scinai Immunotherapeutics Ltd. Extends Maturity of Its Finance Facility with Scinai Immunotherapeutics from 2027 to 2031 CI
Scinai Immunotherapeutics Regains Compliance With Nasdaq's Shareholder Equity Rule MT
Scinai Immunotherapeutics Ltd. Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting Its New CDMO Business Unit CI
European Investment Bank Considers Extending Maturity of Scinai Immunotherapeutics Ltd. of its Financial Facility Contract CI
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ADRs Hold Steady, Medigus Ltd. Climbs 24.5% DJ
Scinai Immunotherapeutics Ltd. announced that it has received $1.329254 million in funding CI
Scinai Immunotherapeutics Closes $1.3 Million Registered Direct Offering MT
Scinai Immunotherapeutics Ltd. announced that it expects to receive $1.329254 million in funding CI
ADRs Close Lower, Scinai Immunotherapeutics Ltd. Declines 15.5% DJ
Scinai Immunotherapeutics Launches $1.33 Million Registered Direct Offering MT
ADRs Advance, Brainsway Ltd. Climbs 14.0% DJ
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday MT
BiondVax Pharmaceuticals Changes Name to Scinai Immunotherapeutics MT
BiondVax Pharmaceuticals Ltd. has Changed its Name to Scinai Immunotherapeutics Ltd CI
BiondVax Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
ADRs End Mostly Lower, BiondVax, Evaxion Biotech Trade Actively DJ
Top Premarket Gainers MT
BiondVax Pharmaceuticals Ltd. Signs Exclusive License Agreement for Development and Commercialization of A Novel Anti-II-17 Antibody for Treatment of Autoimmune and Inflammatory Diseases Including Psoriasis CI
BiondVax Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Scinai Immunotherapeutics Ltd.
More charts
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.519 USD
Average target price
70 USD
Spread / Average Target
+13,387.48%
Consensus
  1. Stock
  2. Equities
  3. Stock Scinai Immunotherapeutics Ltd. - Nasdaq
  4. News Scinai Immunotherapeutics Ltd.
  5. BiondVax Pharmaceuticals Joins German Institutes to Develop COVID-19 Nanosized Antibodies; Shares Surge 97%